In a recent clinical study on CML patients by Ammar et al. (2020), an association was found between elevated levels of P-gp and unresponsiveness to treatment, indicating that the overexpression of P-gp is probably a relevant mechanism in the development of resistance to imatinib [32]. Here, PGP is linked to chronic myelogenous leukemia, BCR-ABL1 positive.